Form 4: Sarepta Therapeutics Executive Dallan Murray Reports Acquisition of 3,500 Shares Through Performance Restricted Stock Units
SEC Form 4 Filing
Chief Customer Officer Dallan Murray reports acquisition of 3,500 shares of Sarepta Therapeutics common stock through performance-based stock units.
Summary
- Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, reported a transaction on February 11, 2025, related to Performance Restricted Stock Units (PSUs).
- Murray acquired 3,500 shares of common stock through the vesting of PSUs.
- These PSUs were granted on March 6, 2023, and the number of shares earned was based on the Compensation Committee's assessment of the company's achievement of specific milestones.
- The earned PSUs will vest on March 6, 2025, contingent upon Murray's continued service to the company.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an executive, tied to performance. It suggests the company met certain milestones, which is mildly positive, but it's not a major event.
Positives
- The vesting of PSUs indicates that Sarepta Therapeutics has achieved certain performance milestones set by the Compensation Committee.
- The acquisition of shares by a key executive could be interpreted as a sign of confidence in the company's future performance.
Risks
- The vesting of the PSUs is contingent upon Dallan Murray's continued service to the company, so his departure before March 6, 2025, would impact the vesting of these units.
Future Outlook
The vesting of the PSUs on March 6, 2025, is contingent upon Dallan Murray's continued service to the company.
Industry Context
This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency into the equity-based compensation of key executives.
Stakeholder Impact
- The vesting of PSUs aligns executive compensation with company performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 2023-03-06 | Date the Performance Restricted Stock Units (PSUs) were granted to Dallan Murray. |
| 2025-02-11 | Date of the transaction where Dallan Murray acquired shares through PSUs. |
| 2025-03-06 | Date the earned PSUs will vest, subject to continued service. |
| 2025-02-13 | Date of the signature on the Form 4 filing. |
Keywords
Sarepta Therapeutics, Dallan Murray, Performance Restricted Stock Units, PSU, Stock Acquisition, Form 4, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.